Relationship between transcriptional factor HOXB9 and evasive resistance in colorectal cancer

转录因子HOXB9诱导人结肠癌细胞株表达转化生长因子β途径的激活和血管生成因子的分泌。在裸鼠移植瘤模型中，高表达HOXB9的裸鼠移植瘤生长明显快于对照组。此外，在贝伐单抗治疗中，高表达HOXB9的异种移植瘤的肿瘤缩小率显著高于对照。因此，转录因子HOXB9可能是贝伐单抗治疗结直肠癌患者的候选生物标记物。

Transcriptional factor HOXB9 induced human colon cancer cell lines expressed activation of TGFβpathway and secretion of angiogenic factors including VEGF. In xenograft model of nude mice, HOXB9 overexpressed xenografts showed much rapider growth than control. Moreover, HOXB9 overexpressed xenografts had significantly higher tumor shrinkage rate than control in the treatment of bevacizumab. Thus, transcriptional factor HOXB9 may be a candidate for a biomarker of the treatment of bevacizumab in colorectal cancer patients.